Fund regulator-ready evidence dossiers for the 20 best-supported off-patent drugs
The evidence for old drugs against cancer is scattered across hundreds of papers. Assembling it into the format regulators and funders need is cheap and would speed decisions.
The Anticancer Fund's ReDO_DB and similar efforts catalogue candidates but stop short of the structured, regulator-grade dossiers (preclinical summary, pharmacology, safety in the target population, systematic review of clinical signals, proposed trial design) that a funder or a third-party label filing needs. The proposal is a funded programme, with methodologists and regulatory writers, that produces and publishes open dossiers for the 20 candidates with the strongest evidence, updated annually, each ending with a prioritised trial proposal and a regulatory strategy.
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
Pages like this
not linked directly; found by shared links- IdeaA guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer
Shares No incentive to repurpose cheap drugs, Knowledge reaches practice too slowly.
- IdeaGet biomarker-directed aspirin after colorectal surgery into labels and guidelines
Shares No incentive to repurpose cheap drugs, Knowledge reaches practice too slowly.
- TrialALASCCA
Shares No incentive to repurpose cheap drugs, Knowledge reaches practice too slowly.